{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-030624","form_type":"8-K","ticker":"FEED","cik":"0001326706","company_name":"ENvue Medical, Inc.","filed_at":"2023-08-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.585092+00:00","generated_at":"2026-06-11T01:50:55.042889+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NanoVibronix reports positive UroShield study; 1/3 of patients saw fewer blockages","bullets":["Approximately one-third of patients reported reduction in catheter blockages and need for unscheduled changes.","Qualitative data showed favorable opinions from majority of participants in the independent study.","Study published on ScienceDirect; investigated UroShield's effect on CAUTI and catheter blockage.","CEO highlights market opportunities and need for alternatives to antibiotics in long-term catheter care."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-030624","json":"https://secwatch.observer/filing/0001493152-23-030624.json","markdown":"https://secwatch.observer/filing/0001493152-23-030624.md","text":"https://secwatch.observer/filing/0001493152-23-030624.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223030624/0001493152-23-030624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223030624/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T01:50:55.042889+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}